- Home
- VVV vs BPMC Comparison
VVV vs BPMC Comparison
Compare VVV & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVV
- BPMC
- Stock Information
- Founded
- VVV 1866
- BPMC 2008
- Country
- VVV United States
- BPMC United States
- Employees
- VVV N/A
- BPMC N/A
- Industry
- VVV Major Chemicals
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- VVV Industrials
- BPMC Health Care
- Exchange
- VVV Nasdaq
- BPMC Nasdaq
- Market Cap
- VVV 4.3B
- BPMC 8.3B
- IPO Year
- VVV 2016
- BPMC 2015
- Fundamental
- Price
- VVV $39.20
- BPMC $128.36
- Analyst Decision
- VVV Buy
- BPMC Buy
- Analyst Count
- VVV 12
- BPMC 20
- Target Price
- VVV $42.75
- BPMC $127.82
- AVG Volume (30 Days)
- VVV 2.1M
- BPMC 3.5M
- Earning Date
- VVV 08-06-2025
- BPMC 07-31-2025
- Dividend Yield
- VVV N/A
- BPMC N/A
- EPS Growth
- VVV 56.15
- BPMC N/A
- EPS
- VVV 2.05
- BPMC N/A
- Revenue
- VVV $1,674,400,000.00
- BPMC $562,121,000.00
- Revenue This Year
- VVV $6.67
- BPMC $44.46
- Revenue Next Year
- VVV $15.40
- BPMC $32.78
- P/E Ratio
- VVV $19.08
- BPMC N/A
- Revenue Growth
- VVV 9.56
- BPMC 99.19
- 52 Week Low
- VVV $31.02
- BPMC $73.04
- 52 Week High
- VVV $48.27
- BPMC $128.75
- Technical
- Relative Strength Index (RSI)
- VVV 63.91
- BPMC 74.76
- Support Level
- VVV $36.41
- BPMC $128.06
- Resistance Level
- VVV $39.90
- BPMC $128.78
- Average True Range (ATR)
- VVV 0.86
- BPMC 0.26
- MACD
- VVV 0.12
- BPMC -1.13
- Stochastic Oscillator
- VVV 81.48
- BPMC 53.85
About VVV Valvoline Inc.
Valvoline Inc produces, markets, and sells automotive maintenance products, particularly lubricants, to retail outlets installers, and customers. The company offers various products such as engine oil, heavy-duty engine oil, motorcycle oil, grease and brake fluid, and others. Geographically, the majority of the revenue is generated from the United States of America.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.